Generic Rivaroxaban ( Rivaroxaban )

Buy Generic Rivaroxaban (Rivaroxaban) without prescription in Canada

In our Canadian pharmacy, you can buy Rivaroxaban without a prescription, with delivery across Canada within 5‑14 days. Discreet and anonymous packaging.

Rivaroxaban, widely known by the brand name Xarelto, is an oral anticoagulant belonging to the class of direct factor Xa inhibitors. It works by selectively and reversibly binding to the active site of factor Xa, a key enzyme in the blood coagulation cascade; this action interrupts both the intrinsic and extrinsic pathways, inhibiting thrombin generation and fibrin clot formation. By reducing the tendency of blood to clot, rivaroxaban is used to prevent and treat venous thromboembolism (deep vein thrombosis and pulmonary embolism) and to reduce the risk of stroke in patients with non‑valvular atrial fibrillation. A 10 mg dose is used primarily for the prevention of blood clots after elective hip or knee replacement surgery and for the extended prevention of recurrent deep vein thrombosis and pulmonary embolism in selected patients after the initial treatment phase is complete.

Usual adult dose: For the prevention of venous thromboembolism (VTE) after elective total hip replacement (THR) or total knee replacement (TKR) surgery, the recommended dose is 10 mg taken orally once daily. The initial dose should be taken 6 to 10 hours after surgery, provided that hemostasis has been established. For patients undergoing THR, treatment is continued for 35 days; for TKR, treatment is continued for 14 days. For the extended prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) following at least 6 months of standard anticoagulation therapy, the dose is 10 mg once daily. Doses of 15 mg and 20 mg must always be taken with food to ensure adequate absorption; the 10 mg dose may be taken with or without food.

Dosage form: Film‑coated oral tablet, 10 mg (as well as 15 mg and 20 mg tablets). A 2.5 mg tablet and granules for oral suspension are also available for specific indications.

Onset of action: Rivaroxaban is rapidly absorbed, with peak plasma concentrations reached within 2 to 4 hours of an oral dose. Inhibition of factor Xa activity occurs within the first hours, and the antithrombotic effect is therefore achieved rapidly after the first dose. Steady‑state pharmacokinetics are reached within approximately 3 days of once‑daily dosing.

Duration of action: The elimination half‑life is approximately 5 to 9 hours in healthy young subjects and 11 to 13 hours in the elderly. The anticoagulant effect is maintained for approximately 24 hours with once‑daily dosing; adherence to the daily schedule is essential because the effect wanes rapidly after a missed dose.

Alcohol recommendation: Alcohol consumption should be limited during treatment with Rivaroxaban. While alcohol does not directly interact with the drug’s metabolism, excessive alcohol intake can independently increase the risk of gastrointestinal bleeding, may impair liver function (which is important for rivaroxaban clearance), and increases the risk of falls and injury in patients taking anticoagulants.

Most common side effects: The most frequent adverse effect is bleeding, which can occur in any tissue or organ. Common bleeding events include epistaxis (nosebleeds), gingival bleeding, easy bruising, and prolonged bleeding from minor wounds. Other common side effects (incidence ≥ 1%) include nausea, fatigue, dizziness, headache, and pruritus. Elevated liver transaminases may occur, and rarely, severe or fatal hemorrhage, including intracranial and gastrointestinal bleeding, has been reported. An increase in all‑cause mortality, thromboembolic events, and bleeding events has been observed with rivaroxaban in patients after transcatheter aortic valve replacement (TAVR), and it is not recommended for this use.

Would you like to try Rivaroxaban without a prescription?

General Information about Rivaroxaban

• INN (International Nonproprietary Name): Rivaroxaban
• Brand names available in Canada: Xarelto® (Bayer Inc.) is the original brand‑name product[reference:0]. Generic versions are widely available and include APO‑Rivaroxaban (Apotex Inc.), PMS‑Rivaroxaban (Pharmascience Inc.), Sandoz Rivaroxaban (Sandoz Canada Inc.), TEVA‑Rivaroxaban (Teva Canada Limited), M‑Rivaroxaban (Mantra Pharma Inc.), JAMP‑Rivaroxaban (JAMP Pharma Corporation), and others[reference:1][reference:2].
• ATC code: B01AF01 (direct factor Xa inhibitors)[reference:3].
• Dosage forms and strengths: Film‑coated tablets: 2.5 mg, 10 mg, 15 mg, and 20 mg. Granules for oral suspension (1 mg/mL) are also available for pediatric use. The 10 mg tablet is round, light‑red, and debossed with “10” and a Bayer cross on one side.
• Manufacturers in Canada: Bayer Inc. (Xarelto). Generic products are manufactured or distributed by Apotex Inc., Pharmascience Inc., Sandoz Canada Inc., Teva Canada Limited, Mantra Pharma Inc., JAMP Pharma Corporation, and other generic pharmaceutical companies.
• Registration status in Canada: Approved by Health Canada. Marketed (DINs: 02378604 [Xarelto 10 mg], 02541475 [Sivem Rivaroxaban 10 mg], and others). The original Xarelto 10 mg tablet was first authorized in Canada on September 15, 2008.[reference:4]
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. Available only with a valid prescription from a licensed Canadian healthcare professional.

Mechanism of Action and Pharmacology

Rivaroxaban is a highly selective, direct factor Xa inhibitor with oral bioavailability. Factor Xa occupies the convergence point of the intrinsic and extrinsic coagulation pathways and catalyzes the conversion of prothrombin to thrombin; one molecule of factor Xa generates more than 1,000 thrombin molecules. Rivaroxaban binds reversibly to the active site of both free and clot‑associated factor Xa, dose‑dependently inhibiting its enzymatic activity. Unlike indirect factor Xa inhibitors such as fondaparinux, rivaroxaban does not require a cofactor (antithrombin) and inactivates both free factor Xa and factor Xa bound within the prothrombinase complex. By inhibiting thrombin generation, rivaroxaban attenuates fibrin formation and platelet activation, thereby preventing thrombus extension and embolization. Rivaroxaban does not directly inhibit thrombin (factor IIa) and has no direct effect on platelets[reference:5].

Following oral administration, rivaroxaban is rapidly absorbed, with maximum plasma concentrations (C_max) appearing 2 to 4 hours after tablet intake. The absolute oral bioavailability of the 10 mg tablet is 80% to 100% and is not affected by food; hence the 10 mg dose can be taken with or without food. In contrast, the 15 mg and 20 mg tablets have a bioavailability of approximately 66% under fasting conditions and must be taken with food to achieve complete absorption. Rivaroxaban is highly protein‑bound (92% to 95%), primarily to albumin. It is metabolized primarily by oxidative degradation via CYP3A4/5 and CYP2J2 and by hydrolysis; it is a substrate of the efflux transporter P‑glycoprotein (P‑gp). Approximately two‑thirds of a dose is excreted as inactive metabolites, with one‑half eliminated renally and one‑half eliminated by the hepatobiliary route; the remaining one‑third is excreted unchanged in the urine as active drug. The elimination half‑life is 5 to 9 hours in healthy young individuals and 11 to 13 hours in the elderly. Rivaroxaban pharmacokinetics are not meaningfully affected by body weight or sex; however, exposure is increased in patients with renal impairment and in those taking combined P‑gp and strong CYP3A inhibitors[reference:6].

Indications

• Prevention of Venous Thromboembolic Events (VTE) after Orthopedic Surgery: Rivaroxaban 10 mg once daily is indicated for the prevention of VTE (deep vein thrombosis and pulmonary embolism) in adults who have undergone elective total hip replacement (THR) or total knee replacement (TKR) surgery[reference:7].
• Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) and Prevention of Recurrent VTE: Higher initial doses (15 mg twice daily for 3 weeks, followed by 20 mg once daily) are used for the acute treatment of DVT and PE. For extended prevention of recurrent DVT and PE beyond 6 months, the dose may be reduced to 10 mg once daily, based on an individual risk‑benefit assessment of recurrent VTE versus bleeding risk[reference:8].
• Stroke and Systemic Embolism Prevention in Non‑Valvular Atrial Fibrillation (NVAF): Rivaroxaban 20 mg once daily (or 15 mg once daily for patients with creatinine clearance 15 to 49 mL/min) is indicated for the prevention of stroke and systemic embolism in adults with non‑valvular atrial fibrillation. The 10 mg dose is not indicated for this purpose[reference:9].
• Secondary Prevention of Atherothrombotic Events (in combination with ASA): Rivaroxaban 2.5 mg twice daily, in combination with acetylsalicylic acid (ASA) 75‑100 mg once daily, is indicated for the prevention of stroke, myocardial infarction, and cardiovascular death, and for the prevention of acute limb ischemia and mortality in patients with coronary artery disease (CAD) with or without peripheral artery disease (PAD)[reference:10].
• Pediatric VTE Treatment and Prevention: Rivaroxaban 15 mg and 20 mg tablets and granules for oral suspension are indicated for the treatment of VTE and prevention of VTE recurrence in children and adolescents under 18 years of age after at least 5 days of initial parenteral anticoagulation[reference:11].

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Rivaroxaban should not be used during pregnancy. The limited available data are insufficient to inform a drug‑associated risk. Animal studies have shown that rivaroxaban crosses the placenta, and there is a potential risk of bleeding and hemorrhagic complications. Women of childbearing potential should use effective contraception during treatment and for at least 30 days after the last dose.
• Breastfeeding: It is not known whether rivaroxaban is excreted in human breast milk. Because of the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment. A decision must be made whether to discontinue breastfeeding or to discontinue the drug.
• Paediatrics (< 18 years): The safety and efficacy of rivaroxaban 10 mg have not been established in children. Pediatric indications are limited to the treatment and prevention of VTE recurrence using the 15 mg and 20 mg tablets or granules for oral suspension, under specialist guidance.
• Elderly (≥ 65 years): No dose adjustment is required based on age alone. However, elderly patients are at increased risk of bleeding, particularly gastrointestinal bleeding, and renal function should be assessed before and periodically during therapy. The elimination half‑life of rivaroxaban is prolonged to 11 to 13 hours in the elderly.
• Renal impairment: For the prevention of VTE after THR or TKR, no dose adjustment is needed for patients with mild to moderate renal impairment (creatinine clearance ≥ 15 mL/min). For the extended prevention of recurrent VTE and for all other indications, rivaroxaban is not recommended in patients with creatinine clearance below 15 mL/min, and should be used with caution in those with CrCl 15 to 29 mL/min. Renal function should be monitored at least annually or more frequently as clinically indicated[reference:12].
• Hepatic impairment: Rivaroxaban is contraindicated in patients with moderate to severe hepatic impairment (Child‑Pugh B or C) associated with coagulopathy and clinically relevant bleeding risk. Patients with severe hepatic impairment have not been studied. Patients with mild hepatic impairment (Child‑Pugh A) may be treated with standard doses[reference:13].
• Mechanical heart valves and moderate‑severe mitral stenosis: Rivaroxaban is contraindicated in patients with mechanical prosthetic heart valves or with moderate to severe mitral stenosis (rheumatic and non‑rheumatic), as safety and efficacy have not been established in these populations[reference:14].
• Antiphospholipid syndrome: Rivaroxaban is not recommended in patients with a history of thrombosis who have been diagnosed with antiphospholipid syndrome, particularly those who are triple‑positive (positive for lupus anticoagulant, anticardiolipin antibodies, and anti‑beta‑2‑glycoprotein I antibodies), due to an increased risk of recurrent thrombotic events compared with warfarin[reference:15].
• Transcatheter aortic valve replacement (TAVR): Rivaroxaban is not indicated and is not recommended for patients after TAVR. A clinical trial in this population demonstrated an increase in all‑cause mortality, thromboembolic events, and bleeding with rivaroxaban compared with antiplatelet therapy[reference:16].
• Neuraxial anesthesia and spinal puncture: Patients receiving rivaroxaban who undergo neuraxial anesthesia (epidural or spinal) or spinal puncture are at risk of developing an epidural or spinal hematoma, which can result in long‑term or permanent paralysis. The risk is increased by the use of indwelling epidural catheters and concomitant medications affecting hemostasis. Rivaroxaban should be discontinued at least 18 hours (for CrCl ≥ 30 mL/min) or 26 hours (for CrCl < 30 mL/min) before an elective neuraxial procedure[reference:17].
• Bleeding risk: Rivaroxaban increases the risk of major and fatal bleeding. It should be used with caution in patients with an increased risk of hemorrhage, such as those with uncontrolled severe hypertension, recent or recurrent gastrointestinal ulceration, vascular retinopathy, recent intracranial hemorrhage, or recent brain, spinal, or ophthalmic surgery. Promptly evaluate any signs or symptoms of blood loss.
• Drug‑induced liver injury: Elevations in liver transaminases (ALT/AST) have been observed. Clinically significant liver injury, including acute liver failure, has been reported rarely. Liver function should be monitored periodically during therapy.
• Allergy: Do not take Rivaroxaban if you have a known hypersensitivity to rivaroxaban or any excipient in the formulation, including lactose. Hypersensitivity reactions including anaphylaxis, angioedema, and severe skin reactions have been reported.

Driving and alcohol

Rivaroxaban may cause dizziness, fatigue, or syncope in some patients. Patients should be aware of how they react to the medication before driving, operating machinery, or engaging in activities that require mental alertness. Alcohol consumption should be limited during treatment with Rivaroxaban. Although there is no direct pharmacokinetic interaction, excessive alcohol intake increases the risk of gastrointestinal bleeding, may impair liver function, and increases the risk of falls and injury in patients taking anticoagulants. Heavy drinking should be avoided.

Dosage Instructions

• Prevention of VTE after THR or TKR: 10 mg once daily. The initial dose should be taken 6 to 10 hours after surgery, once hemostasis is established. For THR, the recommended treatment duration is 35 days; for TKR, 14 days. The 10 mg dose can be taken with or without food.
• Extended prevention of recurrent DVT and PE: After at least 6 months of standard anticoagulation for DVT or PE, rivaroxaban 10 mg once daily may be used for extended prevention, based on an individual risk‑benefit assessment of recurrent VTE versus bleeding risk. No dose adjustment is required for patients with CrCl ≥ 15 mL/min; use is not recommended for CrCl < 15 mL/min[reference:18].
• Acute treatment of DVT and PE: 15 mg twice daily for the first 3 weeks, followed by 20 mg once daily thereafter. Both the 15 mg and 20 mg doses must be taken with food.
• Stroke prevention in NVAF: 20 mg once daily with food for patients with CrCl ≥ 50 mL/min; 15 mg once daily with food for patients with CrCl 15 to 49 mL/min[reference:19].
• Administration: The 10 mg tablet may be taken with or without food. The tablet should be swallowed whole with a glass of water. For patients who are unable to swallow whole tablets, the 10 mg tablet may be crushed and mixed with water or apple puree immediately before administration; this mixture is stable for up to 4 hours. Doses of 15 mg and 20 mg must always be taken with food to ensure adequate absorption.
• Missed dose: If a once‑daily dose is missed, the patient should take the missed dose as soon as remembered on the same day. If it is close to the time of the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. Do not double the dose to make up for a missed one.
• Discontinuation: Discontinuation of rivaroxaban, particularly in patients with atrial fibrillation, is associated with an increased risk of thromboembolic events, including stroke. Rivaroxaban should not be discontinued without consulting the prescribing physician. If discontinuation is required for elective surgery, the timing should be based on renal function: for patients with CrCl ≥ 30 mL/min, the last dose should be taken at least 24 hours before the procedure; for CrCl < 30 mL/min, at least 48 hours before.

Side Effects and Contraindications

• Most common side effects (≥ 1% in clinical trials): Bleeding complications of any severity, including epistaxis (nosebleeds), gingival bleeding, easy bruising (ecchymosis), and prolonged bleeding from minor wounds. Other common adverse effects include nausea, fatigue, dizziness, headache, pruritus, and elevated liver transaminases (ALT/AST).
• Serious adverse reactions: Major or fatal bleeding, including intracranial hemorrhage, gastrointestinal hemorrhage, retroperitoneal hemorrhage, intraocular hemorrhage, and hemarthrosis. Epidural or spinal hematoma may occur in patients who undergo neuraxial anesthesia or spinal puncture. Drug‑induced liver injury, including acute hepatic failure, has been reported rarely. Thrombocytopenia and hypersensitivity reactions (including anaphylaxis, angioedema, Stevens‑Johnson syndrome, and DRESS syndrome) have been reported in post‑marketing experience.
• Laboratory abnormalities: Elevations in ALT, AST, and gamma‑glutamyltransferase (GGT). Decreases in hemoglobin and hematocrit may occur due to occult or overt bleeding. There is no need for routine coagulation monitoring during treatment with rivaroxaban; however, if clinically indicated, rivaroxaban activity can be assessed by calibrated anti‑factor Xa assays. Prothrombin time (PT) measured with Neoplastin reagent shows a dose‑dependent prolongation; the INR is calibrated and validated only for coumarins and should not be used to monitor rivaroxaban[reference:20].
• Contraindications: Hypersensitivity to rivaroxaban or any excipient in the formulation. Active clinically significant bleeding. Lesion or condition at significant risk of major bleeding (e.g., recent gastrointestinal ulcer, malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal, or ophthalmic surgery, known or suspected esophageal varices, arteriovenous malformations, vascular aneurysms, or major intraspinal or intracerebral vascular abnormalities). Hepatic disease associated with coagulopathy and clinically relevant bleeding risk, including Child‑Pugh B and C cirrhotic patients[reference:21]. Mechanical prosthetic heart valves; moderate to severe mitral stenosis[reference:22]. Concomitant treatment with any other anticoagulant, including unfractionated heparin, low molecular weight heparins (enoxaparin, dalteparin), heparin derivatives (fondaparinux), or oral anticoagulants (warfarin, dabigatran, apixaban, edoxaban), except under specific circumstances of switching therapy or when unfractionated heparin is given at doses necessary to maintain a patent central venous or arterial catheter. Pregnancy and breastfeeding. Pediatric use (10 mg tablet) — safety and efficacy not established.

Drug Interactions

• Combined P‑gp and strong CYP3A inhibitors — avoid concomitant use: Ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir, indinavir, and other strong CYP3A4 inhibitors that are also P‑gp inhibitors significantly increase rivaroxaban exposure and the risk of bleeding. Concomitant use should be avoided[reference:23].
• Combined P‑gp and strong CYP3A inducers — avoid concomitant use: Rifampin, rifabutin, carbamazepine, phenytoin, phenobarbital, St. John's wort, and other strong CYP3A4 inducers that are also P‑gp inducers decrease rivaroxaban exposure, potentially reducing its antithrombotic efficacy. Concomitant use should be avoided[reference:24].
• Combined P‑gp and moderate CYP3A inhibitors in patients with renal impairment — avoid concomitant use: Erythromycin, clarithromycin, and fluconazole may increase rivaroxaban exposure to a clinically relevant degree in patients with renal impairment (CrCl 15 to < 80 mL/min). Concomitant use should be avoided unless the potential benefit justifies the potential risk[reference:25].
• Anticoagulants and antiplatelet agents — increased bleeding risk: Concomitant use with other anticoagulants (warfarin, heparin, enoxaparin, dabigatran, apixaban) is contraindicated except when switching therapy. Concomitant use with antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor) or NSAIDs (ibuprofen, naproxen, diclofenac) increases the risk of bleeding. Chronic concomitant use of NSAIDs should be avoided when possible, and patients should be monitored closely for signs of bleeding[reference:26].
• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): These agents (e.g., fluoxetine, sertraline, citalopram, venlafaxine) inhibit platelet serotonin uptake and may further increase the risk of bleeding when used with rivaroxaban. Use with caution and monitor for bleeding.
• Food and alcohol: The 10 mg dose may be taken with or without food. Doses of 15 mg and 20 mg must always be taken with food to ensure adequate absorption. Grapefruit juice, a moderate CYP3A inhibitor, should be consumed in moderation. Alcohol should be limited because of its independent effects on bleeding risk and liver function.

Practical Advice

• Administration: Take Rivaroxaban 10 mg once daily at approximately the same time each day. The 10 mg tablet may be taken with or without food. If you are prescribed the 15 mg or 20 mg tablet, it must be taken with food. Swallow the tablet whole with a glass of water. If you have difficulty swallowing, the 10 mg tablet may be crushed and mixed with water or apple puree immediately before taking. Adherence to the once‑daily schedule is critical: missing a dose significantly increases the risk of a blood clot.
• Monitoring: Renal function (serum creatinine and estimated creatinine clearance) should be assessed before starting therapy and at least annually thereafter, or more frequently in patients with conditions that may decrease renal function. Liver function tests should be monitored periodically. Routine coagulation monitoring (PT/INR, aPTT) is not required. Patients should be educated to recognize signs and symptoms of bleeding (unusual bruising, pink or brown urine, blood in the stools or black/tarry stools, coughing up blood, prolonged nosebleeds, excessive menstrual bleeding) and to seek medical attention promptly if these occur.
• Storage: Store at room temperature (15‑30 °C) in a dry place, protected from moisture and light. Keep out of the reach and sight of children.
• Lifestyle: Carry a medical alert card or wear a medical identification bracelet indicating that you are taking an oral anticoagulant, so that emergency medical personnel are aware. Inform all healthcare professionals—including dentists, surgeons, and pharmacists—that you are taking rivaroxaban before any surgical or dental procedure, and before any new prescription, over‑the‑counter medication, or herbal product is taken. Avoid activities that carry a high risk of injury or bleeding. Use a soft toothbrush and an electric razor to minimize the risk of bleeding. Avoid excessive alcohol intake.
• Missed dose: If you miss a dose, take it as soon as you remember on the same day. If it is almost time for your next dose, skip the missed dose and take your next dose at the usual time. Do not take two doses at once or on the same day to make up for a missed dose.
• When to seek medical review: Seek emergency medical attention immediately if you experience any signs of serious bleeding, including unexplained bleeding that does not stop on its own; vomiting of blood or vomit that looks like coffee grounds; coughing up blood; blood in the urine (pink or dark brown urine); blood in the stool or black, tarry stools; sudden, severe headache, dizziness, or weakness; prolonged nosebleeds (lasting more than 10 minutes); bleeding from the gums; or unusual or heavy menstrual bleeding. Also seek emergency care for signs of a stroke or blood clot: sudden numbness or weakness on one side of the body, trouble speaking or understanding speech, sudden vision changes, or sudden chest pain or shortness of breath. Also seek emergency care for signs of a serious allergic reaction: hives, difficulty breathing, or swelling of the face, lips, tongue, or throat. If a fall or head injury occurs, seek immediate medical evaluation, even if you feel well, because of the risk of intracranial bleeding.
• Disposal: Return unused or expired tablets to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Other direct oral anticoagulants (DOACs): Apixaban (Eliquis®) is another direct factor Xa inhibitor with a similar spectrum of indications. Some observational data suggest that apixaban may be associated with a lower rate of gastrointestinal bleeding compared with rivaroxaban[reference:27]. Dabigatran (Pradaxa®) is a direct thrombin inhibitor that also offers fixed oral dosing without routine laboratory monitoring. Edoxaban (Lixiana®) is another once‑daily factor Xa inhibitor approved in Canada for the prevention of stroke in atrial fibrillation and for the treatment and prevention of VTE.
• Warfarin (Coumadin®): A vitamin K antagonist that has been the standard of care for decades. It requires individualized dosing based on regular INR monitoring, has numerous food and drug interactions, but offers the advantage of a well‑established reversal strategy (vitamin K, prothrombin complex concentrates) and extensive clinical experience. Warfarin remains the preferred anticoagulant in patients with mechanical heart valves, moderate to severe mitral stenosis, antiphospholipid syndrome with a history of thrombosis, and severe renal impairment.
• Low molecular weight heparin (LMWH): Enoxaparin (Lovenox®) and dalteparin (Fragmin®) are parenteral anticoagulants used for the acute treatment of VTE and for bridging therapy. They require daily subcutaneous injection and are preferred in patients with active cancer, in whom DOACs may have a higher risk of bleeding or recurrent thrombosis.
• Fondaparinux (Arixtra®): An indirect, parenteral factor Xa inhibitor that requires once‑daily subcutaneous injection. It is used for the prevention and treatment of VTE, and in patients with heparin‑induced thrombocytopenia (HIT).
• Non‑pharmacological alternatives: For patients undergoing elective orthopedic surgery, mechanical methods of thromboprophylaxis such as intermittent pneumatic compression devices and graduated compression stockings are recommended in combination with anticoagulant therapy, or alone for patients with contraindications to pharmacologic prophylaxis. Early mobilization after surgery is an essential component of VTE prevention.

Clinical Efficacy

The clinical efficacy of rivaroxaban 10 mg for the prevention of VTE after elective hip and knee replacement surgery was established in the RECORD (REgulation of Coagulation in ORthopedic surgery to prevent Deep vein thrombosis and pulmonary embolism) clinical development programme. Four phase III randomized, double‑blind, active‑controlled trials compared rivaroxaban 10 mg once daily (started 6 to 8 hours post‑operatively) with enoxaparin 40 mg once daily (started 12 hours pre‑operatively) or enoxaparin 30 mg twice daily (started 12 to 24 hours post‑operatively). Pooled analyses of the RECORD 1‑4 trials demonstrated that rivaroxaban was significantly more effective than the respective enoxaparin regimens in reducing the composite primary endpoint of any deep vein thrombosis, non‑fatal pulmonary embolism, or all‑cause mortality, with a relative risk reduction of approximately 49% after total hip replacement and 31% after total knee replacement. The rate of major bleeding, including surgical‑site bleeding, was similar between the rivaroxaban and enoxaparin groups[reference:28].

For the treatment and prevention of recurrent VTE, the EINSTEIN programme (EINSTEIN‑DVT, EINSTEIN‑PE, and EINSTEIN‑Extension) demonstrated that rivaroxaban (15 mg twice daily for 3 weeks, followed by 20 mg once daily) was non‑inferior to enoxaparin followed by warfarin for the primary efficacy endpoint of recurrent symptomatic VTE, with a similar safety profile in terms of major and clinically relevant non‑major bleeding. In the EINSTEIN‑Extension study, rivaroxaban 20 mg once daily reduced the rate of recurrent VTE by 82% compared with placebo. A subsequent analysis of EINSTEIN‑Extension demonstrated that a reduced dose of 10 mg once daily, used for extended prevention beyond 6 months, maintained efficacy in preventing recurrent VTE while further reducing the risk of bleeding compared with the 20 mg dose.

For stroke prevention in non‑valvular atrial fibrillation, the landmark ROCKET AF (Rivaroxaban Once‑daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial randomized over 14,000 patients to rivaroxaban 20 mg once daily (15 mg once daily for patients with moderate renal impairment) or dose‑adjusted warfarin (INR 2.0‑3.0). Rivaroxaban was non‑inferior to warfarin for the primary composite endpoint of time to first occurrence of stroke (any type) or non‑central nervous system systemic embolism (hazard ratio 0.79; 95% CI 0.66‑0.96). Rates of major and non‑major clinically relevant bleeding were similar between groups, although rivaroxaban was associated with less intracranial hemorrhage and more gastrointestinal bleeding than warfarin[reference:29].

The CADTH Canadian Drug Expert Committee (CDEC) has recommended that rivaroxaban be reimbursed for the approved indications of VTE prophylaxis after major orthopedic surgery, treatment of acute VTE, prevention of recurrent VTE, and prevention of stroke and systemic embolism in patients with non‑valvular AF[reference:30]. Rivaroxaban is widely listed on provincial drug formularies across Canada, and the innoviCares patient support programme (funded by Bayer Inc.) is available to help eligible patients cover a portion of the cost of brand‑name Xarelto[reference:31].

Important:

Rivaroxaban (Xarelto) is a prescription oral anticoagulant that should be used only under the supervision of a qualified healthcare professional. It can cause serious, life‑threatening bleeding, including intracranial hemorrhage and fatal gastrointestinal bleeding. This risk is increased in patients with renal impairment, those taking concomitant medications that affect hemostasis (aspirin, NSAIDs, other anticoagulants, SSRIs), and those with pre‑existing conditions that predispose to bleeding. Rivaroxaban must not be taken by patients with mechanical prosthetic heart valves or moderate to severe mitral stenosis. It is not recommended for patients with antiphospholipid syndrome and a history of thrombosis, particularly those who are triple‑positive for antiphospholipid antibodies. Adherence to the daily dosing schedule is critical: missing doses increases the risk of stroke and thromboembolism, and the anticoagulant effect wanes rapidly after a missed dose. Do not stop taking rivaroxaban without consulting the prescribing physician. Seek emergency medical attention immediately if you experience any signs of serious bleeding, such as vomiting blood, coughing up blood, blood in the urine or stool, or a sudden severe headache, dizziness, or weakness. Also seek emergency care for signs of a stroke or blood clot. If a fall or head injury occurs, seek immediate medical evaluation even if you feel well. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Rivaroxaban - Shipping across Canada